格隆汇11月19日丨药师帮(09885.HK)公告，11月19日耗资143.5万港元回购20万股。 ...

FF305 公司名稱： 藥師幫股份有限公司 (於開曼群島註冊成立之有限公司) 呈交日期： 2025年11月19日 如上市發行人的已發行股份或庫存股份出現變動而須根據《香港聯合交易所有限公司（「香港聯交所」）證券上市規則》(「《主板上市規則》」)第13.25A條 / 《香港聯合交易所有限公司GEM證券 上市規則》(「《GEM上市規則》」)第17.27A條作出披露，必須填妥第一章節 。 | 第一章節 | | | | | | | | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 1. 股份分類 | 普通股 | 股份類別 | 不適用 | | 於香港聯交所上市 | | 是 | | | 證券代號 (如上市) | 09885 | 說明 | | | | | | | | A. 已發行股份或庫存股份變動 | | | | | | | | | | | | | 已發行股份（不包括庫存股份）變動 | | 庫存股份變動 | | | | | 事件 | | 已發行股份（不包括庫存股份）數 目 | | 佔有關事件前的現有已發 行股份（不包括庫存股 份）數目百分比 (註3) ...

Group 1 - The company, Yaoshi Bang (09885), repurchased 200,000 shares at a total cost of approximately HKD 1.4346 million, with an average repurchase price of HKD 7.1731 per share [1] - Executive Director Chen Fei purchased a total of 200,000 shares in the open market on the same day, indicating confidence in the company's future and growth potential [1] - The board believes that Chen Fei's share acquisition demonstrates his long-term commitment to the company [1]

智通财经APP讯，药师帮(09885)公布，于2025年11月19日，公司耗资约143.46万港元回购20万股股份， 平均回购价为每股7.1731港元。 另外，执行董事陈飞先生已于2025年11月19日在公开市场购入合共20万股股份。董事会认为，陈飞先生 增持股份显示其对公司前景及增长潜力充满信心，亦展示其对公司的长期承诺。 ...

格隆汇11月19日丨药师帮(09885.HK)公告，于2025年11月19日，公司根据2025年股份回购授权回购股 份。合共20万股股份已于市场回购，总回购金额约为1,434,620港元(不包括佣金及其他开支)，平均回购 价为每股7.1731港元。回购股份将适时注销。执行董事陈飞已于2025年11月19日在公开市场购入合共20 万股股份。董事会认为，陈飞增持股份显示其对公司前景及增长潜力充满信心，亦展示其对公司的长期 承诺。 ...

自願性公告 香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不 負 責，對 其 準 確 性 或 完 整 性 亦 不 發 表 任 何 聲 明，並 明 確 表 示，概 不 就 因 本 公 告 全部或任何部分內容所產生或因依賴該等內容而引致的任何損失承擔任何責 任。 股份回購 YSB Inc. 藥師幫股份有限公司 （於 開 曼 群 島 註 冊 成 立 的 有 限 公 司） （股 份 代 號：9885） – 1 – 本 公 司 將 繼 續 遵 守 適 用 於 股 份 回 購 的 相 關 規 則，並 會 及 時 履 行 其 披 露 責 任。 執行董事增持股份 執行董事陳飛先生已於2025年11月19日在公開市場購入合共200,000股 股 份。董 事 會 認 為，陳 先 生 增 持 股 份 顯 示 其 對 本 公 司 前 景 及 增 長 潛 力 充 滿 信 心，亦 展 示 其 對 本 公 司 的 長 期 承 諾。 本 公 司 的 股 份 回 購 計 劃 取 決 於 市 況，並 將 由 董 事 會 全 權 酌 情 決 定。對 於 實 施 股 份 回 購 計 劃 的 時 間、數 目 或 價 格，或 本 公 ...

Core Insights - The company announced a 15% year-on-year revenue growth for the three months ending September 30, 2025, surpassing the revenue growth rate of the first half of 2025 compared to the first half of 2024 [1] - The group's flagship business, including its proprietary brand operations, saw a transaction volume increase of over 120% year-on-year, with proprietary brand transactions growing over 350% in the same period [1] - The flagship business is a key strategic initiative under the "Upward Mobility" plan, significantly contributing to profitability [1] - The company is strategically expanding its proprietary brand product offerings to meet diverse market demands and drive continuous business growth [1]

Core Viewpoint - The company reported a 15% year-on-year increase in revenue for Q3 2025, driven by high-margin businesses such as its proprietary brands and primary push business, which saw transaction volumes grow by 120% and over 350% respectively in October [1][2]. Group 1: Company Performance - The rapid growth in performance is attributed to the company's "upward" strategy, focusing on enhancing supply chain capabilities and optimizing product structure [2]. - The proprietary brand business has significantly contributed to the company's profitability, with a notable increase in customer loyalty and repurchase rates due to high-quality, cost-effective products [2]. - The overall revenue growth in Q3 2025 is notably higher than the growth rate observed in the first half of 2025 compared to the first half of 2024, indicating strong performance despite industry challenges [1]. Group 2: Industry Context - The domestic pharmaceutical retail industry is undergoing a deep adjustment and transformation, facing challenges such as rising compliance costs and accelerated market clearing [1]. - The fourth quarter is traditionally a peak sales season for pharmaceuticals, with expectations that companies will exceed previous conservative performance forecasts due to increased flu activity compared to the previous year [3]. - The company's sales of flu-related medications increased by 36% year-on-year in October, with proprietary brand "Le Yaoshi" cold medications seeing a growth of over 135% [3].

Core Viewpoint - The company reported a 15% year-on-year increase in revenue for Q3 2025, driven by high-margin businesses such as its proprietary brands and first-push products, which saw transaction growth of 120% and over 350% respectively in October, enhancing customer loyalty and improving overall gross margin structure [1][2]. Group 1: Company Performance - The rapid growth in performance is attributed to the company's "upward" strategy, focusing on supply chain enhancement and product structure optimization, which includes strengthening strategic partnerships with upstream pharmaceutical companies and building a smart supply chain system [2]. - The proprietary brand business has shown significant growth, with sales scale increasing rapidly, contributing positively to the company's profitability and improving the overall gross margin structure [2][3]. - The company has maintained a double-digit revenue growth rate in a challenging domestic pharmaceutical retail environment, outperforming the growth rate from the first half of 2025 compared to the same period in 2024 [1]. Group 2: Industry Context - The pharmaceutical retail industry is currently undergoing a deep adjustment and transformation, facing challenges such as rising compliance costs and accelerated market clearing, impacting both upstream pharmaceutical companies and downstream retail pharmacies [1]. - The fourth quarter is traditionally a peak season for pharmaceutical sales, with expectations that companies' performance in Q3 and the second half of the year will exceed previous conservative forecasts, particularly due to a significant increase in flu activity compared to the previous year [3]. - The overall business growth and rapid development of high-value-added services validate the company's strategic shift from scale growth to quality growth, with upstream supply chain advantages and product differentiation becoming key to sustained performance [2].

Core Viewpoint - The company reported a revenue growth of over 15% year-on-year for the three months ending September 30, 2025, surpassing the revenue growth rate for the first half of 2025 compared to the first half of 2024 [1] Group 1: Financial Performance - The total transaction volume for the company's flagship brand promotion business increased by over 120% year-on-year in October 2025 [1] - The transaction volume for the company's own brand business saw a significant increase of over 350% during the same period [1] Group 2: Strategic Initiatives - The flagship brand promotion business is a key strategy in the company's "upward movement" plan and is crucial for enhancing profitability [1] - The company is strategically advancing the expansion of its own brand products, aiming to launch a diverse range of high-quality products that closely align with market demands [1]